(Total Views: 103)
Posted On: 03/11/2025 12:37:49 PM
Post# of 47151
$CVM Key aspects of the new Confirmatory Registration Study are as follows:
Enlisting clinical sites and investigators in numerous countries across 3 continents
Full enrollment expected by Q2 2026 with plans to seek early approval at that time based on early tumor responses—Potential to set a new standard of care
FDA concurred with the overall design of the Registration Study in meetings last year
Final clinical protocol submitted to FDA in December 2024
Multikine extended median overall survival by nearly 4 years in prior Phase 3 study
A new model for healthcare—Immunotherapy given before surgery to boost the immune system and make the first cancer treatment more successful - may set the first new standard of care in more than half a century
https://finance.yahoo.com/news/cel-sci-initia...00000.html
Enlisting clinical sites and investigators in numerous countries across 3 continents
Full enrollment expected by Q2 2026 with plans to seek early approval at that time based on early tumor responses—Potential to set a new standard of care
FDA concurred with the overall design of the Registration Study in meetings last year
Final clinical protocol submitted to FDA in December 2024
Multikine extended median overall survival by nearly 4 years in prior Phase 3 study
A new model for healthcare—Immunotherapy given before surgery to boost the immune system and make the first cancer treatment more successful - may set the first new standard of care in more than half a century
https://finance.yahoo.com/news/cel-sci-initia...00000.html
(0)
(0)
